Rain Therapeutics Experimental Cancer Therapy Shows Encouraging Tumor Regression Activity
Rain Therapeutics Inc (NASDAQ:RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. “Treatment…